Home > Publications database > Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer. > print

001     298342
005     20250821120816.0
024 7 _ |2 pmid
|a pmid:39876058
024 7 _ |2 ISSN
|a 1574-7891
024 7 _ |2 ISSN
|a 1878-0261
024 7 _ |2 doi
|a 10.1002/1878-0261.13814
024 7 _ |2 altmetric
|a altmetric:173649368
037 _ _ |a DKFZ-2025-00246
041 _ _ |a English
082 _ _ |a 610
100 1 _ |0 P:(DE-He78)f2f38d242b5d8cb3903e0ed098e8b554
|a Vlachavas, Efstathios-Iason
|b 0
|e First author
|u dkfz
245 _ _ |a Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer.
260 _ _ |a Hoboken, NJ
|b John Wiley & Sons, Inc.
|c 2025
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1749820765_4026
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
500 _ _ |a #EA:B050#LA:B050# / 2025 Jun;19(6):1751-1774
520 _ _ |a Colorectal cancer (CRC) patients with microsatellite-stable (MSS) tumors are mostly treated with chemotherapy. Clinical benefits of targeted therapies depend on mutational states and tumor location. Many tumors carry mutations in KRAS proto-oncogene, GTPase (KRAS) or B-Raf proto-oncogene, serine/threonine kinase (BRAF), rendering them more resistant to therapies. We performed whole-exome sequencing and RNA-Sequencing of 28 tumors of the Athens Comprehensive Cancer Center CRC cohort, and molecularly characterized CRC patients based on their microsatellite instability (MSI) status, single-nucleotide variations (SNVs)/copy number alterations (CNAs), and pathway/transcription factor activities at the individual patient level. Variants were classified using a computational score for integrative cancer variant annotation and prioritization. Complementing this with public multi-omics datasets, we identified activation of transforming growth factor beta (TGFβ) signaling to be more strongly activated in MSS patients, whereas Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and mitogen-activated protein kinase (MAPK) molecular cascades were activated specifically in MSI tumors. We unraveled mechanisms consistently perturbed in the transcriptional and mutational circuits and identified Runt-related transcription factors (RUNX transcription factors) as putative biomarkers in CRC, given their role in the regulation of pathways involved in tumor progression and immune evasion. Assessing the immunogenicity of CRC tumors in the context of RAS/RAF mutations and MSI/MSS status revealed a critical impact that KRAS mutations have on immunogenicity, particularly in the MSS patient subgroup, with implications for diagnosis and treatment.
536 _ _ |0 G:(DE-HGF)POF4-312
|a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |2 Other
|a CRC
650 _ 7 |2 Other
|a MSI status
650 _ 7 |2 Other
|a RAS/RAF
650 _ 7 |2 Other
|a SNVs/CNAs
650 _ 7 |2 Other
|a WES/RNA‐sequencing
650 _ 7 |2 Other
|a pathway/TF activity
700 1 _ |0 0000-0001-7163-7381
|a Voutetakis, Konstantinos
|b 1
700 1 _ |a Kosmidou, Vivian
|b 2
700 1 _ |0 P:(DE-He78)e2ea2ff7ded515543f890b6cb79dbee7
|a Tsikalakis, Spyridon
|b 3
700 1 _ |a Roditis, Spyridon
|b 4
700 1 _ |a Pateas, Konstantinos
|b 5
700 1 _ |a Kim, Ryangguk
|b 6
700 1 _ |a Pagel, Kymberleigh
|b 7
700 1 _ |0 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
|a Wolf, Stephan
|b 8
|u dkfz
700 1 _ |0 P:(DE-He78)13b64bdd8d9a2fdb2ab13cc480819130
|a Warsow, Gregor
|b 9
|u dkfz
700 1 _ |0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|a Dimitrakopoulou-Strauss, Antonia
|b 10
|u dkfz
700 1 _ |a Zografos, Georgios N
|b 11
700 1 _ |a Pintzas, Alexander
|b 12
700 1 _ |0 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
|a Betge, Johannes
|b 13
|u dkfz
700 1 _ |0 0000-0003-3896-4270
|a Papadodima, Olga
|b 14
700 1 _ |0 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52
|a Wiemann, Stefan
|b 15
|e Last author
|u dkfz
773 _ _ |0 PERI:(DE-600)2322586-5
|a DOI:10.1002/1878-0261.13814
|n 6
|p 1751-1774
|t Molecular oncology
|v 19
|x 1574-7891
|y 2025
909 C O |o oai:inrepo02.dkfz.de:298342
|p VDB
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)f2f38d242b5d8cb3903e0ed098e8b554
|a Deutsches Krebsforschungszentrum
|b 0
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)e2ea2ff7ded515543f890b6cb79dbee7
|a Deutsches Krebsforschungszentrum
|b 3
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)1efb774993effe7a66a6ffc1b1cf9ccb
|a Deutsches Krebsforschungszentrum
|b 8
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)13b64bdd8d9a2fdb2ab13cc480819130
|a Deutsches Krebsforschungszentrum
|b 9
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|a Deutsches Krebsforschungszentrum
|b 10
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c
|a Deutsches Krebsforschungszentrum
|b 13
|k DKFZ
910 1 _ |0 I:(DE-588b)2036810-0
|6 P:(DE-He78)f6bebe05e7a748d3cbf9f59659567d52
|a Deutsches Krebsforschungszentrum
|b 15
|k DKFZ
913 1 _ |0 G:(DE-HGF)POF4-312
|1 G:(DE-HGF)POF4-310
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Krebsforschung
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2025
915 _ _ |0 StatID:(DE-HGF)3001
|2 StatID
|a DEAL Wiley
|d 2025-01-07
|w ger
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2024-08-08T17:04:26Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Open peer review
|d 2024-08-08T17:04:26Z
915 _ _ |0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|a Creative Commons Attribution CC BY (No Version)
|b DOAJ
|d 2024-08-08T17:04:26Z
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0600
|2 StatID
|a DBCoverage
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b ASC
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)9905
|2 StatID
|a IF >= 5
|b MOL ONCOL : 2022
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2025-01-07
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2025-01-07
920 2 _ |0 I:(DE-He78)B050-20160331
|k B050
|l B050 Molekulare Genomanalyse
|x 0
920 1 _ |0 I:(DE-He78)B050-20160331
|k B050
|l B050 Molekulare Genomanalyse
|x 0
920 1 _ |0 I:(DE-He78)W190-20160331
|k W190
|l Hochdurchsatz-Sequenzierung
|x 1
920 1 _ |0 I:(DE-He78)W610-20160331
|k W610
|l Core Facility Omics IT
|x 2
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 3
920 1 _ |0 I:(DE-He78)B440-20160331
|k B440
|l NWG-KKE Translationale Gastrointestinale Onkologie und präklinische Modelle
|x 4
920 0 _ |0 I:(DE-He78)B050-20160331
|k B050
|l B050 Molekulare Genomanalyse
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B050-20160331
980 _ _ |a I:(DE-He78)W190-20160331
980 _ _ |a I:(DE-He78)W610-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)B440-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21